119
10
1
13
2
Cat. No. | Product Name | ||
---|---|---|---|
L2190 | 抗肺癌化合物库 | 1702 compounds | |
1702 种与肺癌相关的化合物,可以用于抗肺癌药物研发和药理研究; |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9460 |
iMDK
|
PI3K | PI3K/Akt/mTOR signaling |
iMDK 是PI3K 抑制剂,能够抑制生长因子MDK。它能够与 MEK 抑制剂协同抑制非小细胞肺癌,而不会伤害正常细胞和小鼠。 | |||
T9929 |
Ramucirumab
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Ramucirumab 是一种人 VEGFR-2 拮抗剂,具有抗实体瘤活性。它是人源化单克隆抗体,能够与 VEGFR-2 结合,阻碍 VEGFR 配体 VEGF-A,VEGF-C 和 VEGF-D 结合。 | |||
T6455 |
CP-91149
|
Phosphorylase | Metabolism |
CP91149 是GP (糖原磷酸化酶)的抑制剂,能够促进糖原的重新合成,但不会造成糖原的过度积累。它对2型糖尿病具有潜在的研究价值。 | |||
T6734 |
WZ8040
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
WZ8040 是一种新型突变选择性不可逆 EGFRT790M 抑制剂,可抑制EGFR 磷酸化。它对突变型EGFR 的活性是野生型EGFR 的100倍以上。 | |||
T8732 |
CTPI-2
|
Others; Mitochondrial Metabolism | Metabolism; Others |
CTPI-2 是一种特异性线粒体柠檬酸盐载体SLC25A1抑制剂,KD=3.5 μM,具有抗肿瘤作用。它能够抑制糖酵解、PPARγ 及其下游靶点葡萄糖转运蛋白 GLUT4。它阻断非酒精性脂肪性肝炎逆转脂肪变性的显著改变,防止演变为脂肪性肝炎,减少肝脏和脂肪组织中炎性巨噬细胞的浸润,并显著减轻由高脂肪饮食引起的肥胖。 | |||
T40254 |
MRTX-1719
|
Histone Methyltransferase | Chromatin/Epigenetic |
MRTX-1719 是有效的PRMT5/MTA 复合体选择性抑制剂,其对PRMT5/MTAMTAPDELSDMA 细胞系的IC50值为 <10 nM。 | |||
T10777 |
CG347B
|
HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
CG347B 是一种选择性HDAC6抑制剂。 | |||
T11224 |
Rineterkib
ERK-IN-1 |
ERK; Raf | MAPK |
Rineterkib (ERK-IN-1) 是口服有效的RAF 和ERK1/2的抑制剂,与 KRAS-突变型非小细胞肺癌、BRAF-突变型非小细胞肺癌、KRAS-突变型胰腺癌、KRAS -突变型结肠癌和 KRAS-突变型卵巢癌尤为相关。 | |||
T13176 |
TNO155
Batoprotafib |
Phosphatase | Metabolism |
TNO155 是具有口服活性野生型SHP2的选择性变构抑制剂 (IC50= 0.011 µM)。它有研究 RTK 依赖性恶性肿瘤(尤其是晚期实体瘤)的潜力。 | |||
T12695 |
RBN-2397
|
PARP | Chromatin/Epigenetic; DNA Damage/DNA Repair |
RBN-2397 是一种有效的、选择性的、具有口服活性的跨物种 NAD+ 竞争性 PARP7 抑制剂,IC50 小于 3 nM。它选择性结合 PARP7 ,Kd 为0.001 μM,可恢复干扰素 I 型信号转导,有用于晚期或转移性实体肿瘤的研究潜力。 | |||
T5414 |
Glumetinib
SCC244 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Glumetinib (SCC244) 是一种高选择性、ATP 竞争性的、口服具有活力的 c-Met 抑制剂。它对 c-Met 的选择性超过 312 种激酶,包括 c-Met 家族成员 RON 和高度同源的激酶 Axl、Mer、TyrO3。它具有抗肿瘤作用。 | |||
T8684 |
Sotorasib
AMG-510 |
Ras | GPCR/G Protein; MAPK |
Sotorasib (AMG-510) 是一种 KRAS G12C 共价抑制剂,具有口服活性和选择性。Sotorasib 与 KRAS G12C 非活性构象的 GDP 状态结合,抑制 KRAS 及其下游信号的传导。Sotorasib 对 KRAS G12C 突变肿瘤具有抑制活性。 | |||
T22318 |
Taletrectinib
DS-6051b,AB-106 |
Trk receptor; ROS; ROS Kinase | Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Taletrectinib (AB-106) 是具有口服活力的、选择性的 ROS1/NTRK 抑制剂。它对重组 ROS1、NTRK1、NTRK2 和 NTRK3 有较强的抑制作用,IC50值分别为 0.207、0.622、2.28 和 0.98 nM。它还抑制 ROS1 G2032R 和其他抗 Crizotinib 的 ROS1 突变体。 | |||
T8327 |
ONO-7475
|
Trk receptor; TAM Receptor | Tyrosine Kinase/Adaptors |
ONO-7475 是一种选择性的、有效的、具有口服活性的Axl/Mer 抑制剂。它使 AXL 过表达的EGFR 突变型 NSCLC 细胞对 EGFR-TKIs 敏感,抑制耐药细胞的产生和耐药性的维持。它与 Osimertinib 联合使用,具有用于 EGFR 突变非小细胞肺癌的潜力。 | |||
T39275 |
Befotertinib
D-0316,Befotertinib |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Befotertinib (D-0316) 是一种 EGFR 酪氨酸激酶抑制剂,可用于 EGFR T790M 阳性非小细胞肺癌的研究。 | |||
T8151 |
Mobocertinib
tak788 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Mobocertinib (tak788) 是可口服的EGFR 和HER2突变的抑制剂,具有抗肿瘤活性。 | |||
T22254 |
Alflutinib
AST2818,ASK120067 |
EGFR; P450 | Angiogenesis; JAK/STAT signaling; Metabolism; Tyrosine Kinase/Adaptors |
Alflutinib (ASK120067) 是 EGFR 抑制剂。 它对 T790M 的性耐药突变以及 EGFR 活性突变具有抑制作用。它对于癌症疾病,特别是非小细胞肺癌(NSC-LC)方面具有研究潜力。 | |||
T16996 |
TAS6417
|
Apoptosis; EGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
TAS6417 是一种高效的、具有口服活性的 EGFR 突变型抑制剂,可独特的结合到 EGFR 铰链区的 ATP 结合位点,其 IC50值为 1.1-8.0 nM。 | |||
T5462 |
Almonertinib
HS-10296,阿美替尼 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Almonertinib (HS-10296) 是EGFR 激活突变抑制剂和EGFR T790M 耐受突变抑制剂,对 EGFR 致敏和 T790M 耐药突变具有高选择性,用于非小细胞肺癌的研究。它对 T790M、T790M/L858R 和 T790M/Del19 表现出较强的抑制活性,对野生型的抑制作用较弱。 | |||
TQ0255 |
Olafertinib
CK-101,EGFR-IN-3,RX-518 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Olafertinib (RX-518) 是新型突变选择性、不可逆、可口服的EGFR 酪氨酸酶抑制剂,可克服 NSCLC 中 T790M 介导的耐药性。 | |||
T22443 |
Triglycidyl isocyanurate
Tris(2,3-epoxypropyl) Isocyanurate,Teroxirone,TGIC,1,3,5-三缩水甘油-S-三嗪三酮,TGI |
Apoptosis | Apoptosis |
Triglycidyl isocyanurate (Teroxirone) 是一种三氮烯三环氧化合物,可通过 p53的激活抑制非小细胞肺癌细胞的生长。它诱导细胞凋亡,具有抗血管生成和抗肿瘤活性,用于癌症研究。 | |||
T16545 |
Pivanex
Pivalyloxymethyl butyrate,AN-9 |
Apoptosis; HDAC; Bcr-Abl | Angiogenesis; Apoptosis; Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair; Tyrosine Kinase/Adaptors |
Pivanex (Pivalyloxymethyl butyrate) 是丁酸的一种衍生物,是具有口服活性的 HDAC 抑制剂。Pivanex 通过下调 bcr-abl 蛋白增强凋亡。Pivanex 显示出抗转移和抗血管生成的活性。 | |||
T7175 |
Alflutinib mesylate
甲磺酸伏美替尼,AST2818 mesylate |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Alflutinib mesylate (AST2818 mesylate) 是一种不可逆的酪氨酸激酶抑制剂,可选择性抑制 EGFR 突变。 | |||
T15735 |
Leptomycin B
CI 940,LMB,来普霉素B |
CRM1; Antibiotic; Antifungal | Membrane transporter/Ion channel; Microbiology/Virology |
Leptomycin B (LMB) 是一种抗真菌抗生素,可阻断真核细胞周期,抑制蛋白出核转运。Leptomycin 通过半胱氨酸残基处的共价修饰使 CRM1/exportin 1失活。它 | |||
T3061 |
Lorlatinib
劳拉替尼,PF-6463922,PF-06463922,Loratinib |
Apoptosis; Tyrosine Kinases; ROS; ALK; ROS Kinase | Angiogenesis; Apoptosis; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Lorlatinib (PF-6463922) 是一种具有口服活性,选择性,脑渗透性和 ATP 竞争性的ROS1/ALK 抑制剂,具有抗癌活性。它对 ROS1、野生型 ALK 和 ALKL1196M 的Ki 值分别为 <0.025 nM、<0.07 nM 和 0.7 nM。 | |||
T20168 |
Aurothiomalate sodium
金硫丁二钠,Myocrisin,Myocrisine,Miochrysin,Sodium aurothiomalate,Myochrysine,gold sodium thiomalate |
Others; PKC | Chromatin/Epigenetic; Cytoskeletal Signaling; Others |
Aurothiomalate sodium (Miochrysin) 是一种选择性的致癌 PKCι信号传导抑制剂,可抑制肿瘤细胞增殖。它是一种硫氧还蛋白还原酶 (TrxR) 抑制剂,也是一种抗风湿剂。 | |||
T8656 |
CAY10404
3-(4-METHYLSULPHONYLPHENYL)-4-PHENYL-5-T |
Apoptosis; Akt; COX | Apoptosis; Cytoskeletal Signaling; Immunology/Inflammation; Neuroscience; PI3K/Akt/mTOR signaling |
CAY10404 (3-(4-METHYLSULPHONYLPHENYL)-4-PHENYL-5-T) 是一种有效且高度选择性的 COX-2 和 COX-1 抑制剂。 它还是 PKB/Akt 和 MAPK 信号通路的有效抑制剂,可诱导 NSC-LC 细胞凋亡,具有镇痛、抗炎和抗癌活性。 | |||
T21312 |
Afatinib
阿法替尼,Afatinib free base,BIBW 2992 |
EGFR; Autophagy | Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Afatinib (BIBW 2992) 是一种不可逆的 EGFR 家族抑制剂,抑制 EGFRwt、EGFRL858R、EGFRL858R/T790M 和 HER2的 IC50分别为0.5 nM、0.4 nM、10 nM 和 14 nM。 | |||
T6823 |
E3330
|
HIF/HIF Prolyl-Hydroxylase; DNA/RNA Synthesis | Cell Cycle/Checkpoint; Chromatin/Epigenetic; DNA Damage/DNA Repair; Metabolism |
E3330 是一种口服有效的选择性 AP 内切核酸酶 1 (APE1; REF-1) 抑制剂,可抑制NF-κB DNA 结合活性。它阻断 TNF-α 诱导的肝癌细胞系中 IL-8 的激活,可以抑制癌细胞的生长和迁移,具有抗癌活性。 | |||
T16492 |
PF-06459988
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PF-06459988 是一种新型的的、有效的、具有口服活性的、不可逆的和选择性的表皮生长因子受体( EGFR) 突变体抑制剂。PF-06459988 对含 T790M 的 EGFRs 双突变体具有高效性和高亲和力,对 WT EGFR 具有极小的活性。PF-06459988 使治疗癌症的候选药物。 | |||
T6804 |
Chetomin
Chaetomin,NSC289491,BRN0077366 |
Apoptosis; HSP; HIF | Angiogenesis; Apoptosis; Chromatin/Epigenetic; Cytoskeletal Signaling; Metabolism |
Chetomin (BRN0077366) 是球毛壳菌的活性成分,是一种无毒的非小细胞肺癌干细胞靶向分子。它是一种热休克蛋白90/缺氧诱导因子1α 途径的抑制剂。 | |||
T1773 |
Afatinib Dimaleate
马来酸阿法替尼,双马来酸盐阿法替尼,BIBW2992,Afatinib,BIBW 2992MA2,Afatinib (BIBW2992) Dimaleate |
EGFR; HER; Autophagy | Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Afatinib Dimaleate (BIBW 2992MA2) 是一种可口服的苯胺基-喹唑啉衍生物和受体酪氨酸激酶表皮生长因子受体家族的抑制剂,具有抗肿瘤活性。它抑制 EGFRwt、EGFRL858R、EGFRL858R/T790M 和 HER2的 IC50分别为0.5 nM、0.4 nM、10 nM 和 14 nM。 | |||
T5675 |
Almonertinib hydrochloride
HS-10296 hydrochloride,盐酸阿美替尼 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Almonertinib hydrochloride (HS-10296 hydrochloride) 是一种 EGFR 激活突变和 T790M 耐药突变的小分子抑制剂,用于非小细胞肺癌的研究,对 T790M、T790M/L858R 和 T790M/Del19 表现出较强的抑制活性,对野生型的抑制作用较弱。 | |||
T11162 |
EGFR-IN-8
|
EGFR; c-Met/HGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-8 是 EGFR 和 c-Met 的双重抑制剂。 EGFR-IN-8可用于靶向 EGFR TKI 耐药的 NSCLC 的研究。 | |||
T6269 |
Bemcentinib
R428,BGB324 |
TAM Receptor | Tyrosine Kinase/Adaptors |
Bemcentinib (R428) 是具有选择性的、高效的 Axl 抑制剂,其 IC50=14 nM。 | |||
T9601 |
Tepotinib hydrochloride(1 : x)
|
c-Met/HGFR; P-gp; ABC | Membrane transporter/Ion channel; Neuroscience; Tyrosine Kinase/Adaptors |
Tepotinib hydrochloride(1 : x) 是一种口服生物可利用的间充质-上皮转化 (MET) TKI,主要针对具有 METex14 跳跃突变的特定 NSCLC 患者开发。 | |||
T9901A-002 |
Enoblituzumab
MGA271,TJ-271 |
Others | Others |
Enoblituzumab 是一种人源化 IgG1κ 单克隆抗体,可以识别人 B7-H3 蛋白 ,可用于研究非小细胞肺癌 (NSCLC)等实体肿瘤。 | |||
T3181 |
SW044248
|
Topoisomerase | DNA Damage/DNA Repair |
SW044248 是非典型拓扑异构酶 I 抑制剂,对 NSCLC 细胞具有选择性毒性。 | |||
T67934 |
MRT-2359
|
Others | Others |
MRT-2359 是一种有效的且可口服的 GSPT1 降解剂,具有抗肿瘤活性。MRT-2359 对耐药非小细胞肺癌 (NSCLC) 和小细胞肺癌 (SCLC) 细胞的生长具有抑制作用。MRT-2359 在 MYC 驱动的细胞系中表现出优先活性。 | |||
T36404L |
PRLX-93936 HCL
PRLX-93936 hcl(903499-49-0 Free base) |
Ferroptosis; Reactive Oxygen Species | Apoptosis; Immunology/Inflammation; Metabolism; NF-κB |
PRLX-93936 HCL 是 erastin 的类似物,并显示出与顺铂对非小细胞肺癌 (NSCLC) 细胞的协同作用。 | |||
T6092 |
Sapitinib
沙普替尼,AZD-8931 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Sapitinib (AZD-8931) 是可逆的 ATP 竞争型 EGFR 抑制剂,对 EGFR、ErbB2 和 ErbB3的IC50值分别为4、3 和 4 nM。 | |||
T72043 |
SCFSkp2-IN-2
|
Apoptosis; E1/E2/E3 Enzyme | Apoptosis; Ubiquitination |
SCFSkp2-IN-2 是一种 Skp2抑制剂,其 KD 为 28.77 μM。AAA-237 诱导 NSCLC 细胞凋亡 (apoptosis),显示出抗肿瘤活性。 | |||
T76873 |
Nidanilimab
CAN04 |
IL Receptor | Immunology/Inflammation |
Nidanilimab (CAN04) 是一种完全人源化的 IL1RAP 单克隆抗体,其 Kd 值为 1.10 pM。Nidanilimab 具有抗肿瘤活性,切断 IL1α 和 IL1β 信号通路,并诱导免疫系统破坏肿瘤细胞。Nidanilimab 可用于研究非小细胞肺癌 (NSCLC) 和胰腺导管腺癌 (PDAC) 等实体癌。 | |||
T35901 |
EGFR-IN-99
JBJ-03-142-02 |
EGFR; HER | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-99 (JBJ-03-142-02) 是一种 EGFR 和 HER2 Exon 20 插入突变抑制剂,具有抗增殖活性,可用于研究非小细胞肺癌 (NSCLC) 。 | |||
T61016 |
EMI1
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EMI1 是 EGFR 三重突变体 (EGFR ex19del/T790M/C797S, EGFR L858R/T790M/C797S) 的有效抑制剂。EMI1 可用于 EGFR 突变相关的耐药型非小细胞肺癌 (NSCLC) 的研究。 | |||
T9754 |
BLU-945
BLU945,BLU 945 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
BLU-945 是一种强效的、高选择性的、口服有效的、可逆的表皮生长因子受体酪氨酸激酶抑制剂 (TKIs)。BLU-945 可有效抑制具有 L858R 和/或外显子 19 缺失突变、T790M 突变和 C797S 突变的 EGFR。BLU-945 可用于肺癌包括非小细胞肺癌(NSCLC)的研究。 | |||
T35391 |
Vibostolimab (anti-TIGIT)
Vibostolimab (anti-TIGIT) |
Others | Others |
Vibostolimab 是一种抗 T 细胞免疫蛋白和 ITIM 域的单克隆抗体。Vibostolimab 在体外实验中显示出抗肿瘤活性,可用于研究非小细胞肺癌 (NSCLC) 和黑色素瘤。 | |||
T4605 |
NT157
|
IGF-1R; STAT | JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
NT157 是一种口服生物可利用的间充质-上皮转化 (MET) TKI,主要针对具有 METex14 跳跃突变的特定 NSCLC 患者开发。 | |||
T10745 |
CDK9-IN-7
|
CDK | Cell Cycle/Checkpoint |
CDK9-IN-7 (compound 21e) 是一种高效选择性的,具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM),与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡,在 G2 期阻滞细胞周期,并具有抑制非小细胞肺癌干细胞特性。 | |||
T15384 |
Glesatinib
MGCD265 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN2108 |
Protohypericin
|
Others | Others |
Protohypericin 是一种从贯叶连翘中提取的天然石脑粉。放射性碘化 Protohypericin 能用于肿瘤坏死靶向放射研究。 | |||
T4903 |
Heptadecanoic acid
|
Others; Endogenous Metabolite | Metabolism; Others |
Heptadecanoic acid 是奇链饱和脂肪酸,与一些疾病(如冠心病、糖尿病前期和 2 型糖尿病以及多发性硬化症)有关。 | |||
TN1153 |
Polyporenic acid C
猪苓酸C,聚孔酸C |
Apoptosis; PARP; Caspase; PI3K | Apoptosis; Chromatin/Epigenetic; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling; Proteases/Proteasome |
Polyporenic acid C 是从茯苓中分离出的一种羊毛甾烷型三萜,可通过死亡受体介导的凋亡途径诱导细胞凋亡,有用于肺癌的研究潜力。 | |||
T34394 |
Rotenolone
12ALPHA-羟基鱼藤酮,Rotenolone I,12alpha-HYDROXYROTENONE |
Others | Others |
Rotenolone (12alpha-HYDROXYROTENONE) 是鱼藤酮的代谢物,鱼藤酮是一种源自藤本植物和龙果属植物的天然化合物。 | |||
T3S0153 |
Xanthatin
苍耳亭,叶黄制菌素 |
Apoptosis; VEGFR; Lipoxygenase; Wnt/beta-catenin; Antibacterial | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Metabolism; Microbiology/Virology; Stem Cells; Tyrosine Kinase/Adaptors |
Xanthatin 是一种从Xanthium strumarium 叶子中提取的天然产物,可诱导细胞凋亡。它抑制布鲁氏菌的IC50值为 2.63 μg/ mL,对寄生虫特异性锥虫硫磷还原酶具有不可逆的弱抑制作用。它通过抑制PGE2的合成和 5-脂氧合酶的活性而显示出抗炎活性。 | |||
TN3972 |
Epimedokoreanin B
|
Apoptosis; Others; Antibacterial | Apoptosis; Microbiology/Virology; Others |
Epimedokoreanin B (EKB) 是一种从韩国淫羊藿中分离出的异戊烯化类黄酮,在人非小细胞肺癌(NSCLC)A549和NCI-H292细胞中展现出抗癌活性。Epimedokoreanin B 还具有抗炎和抗菌活性,可有清除 DPPH 自由基的活性,能以剂量依赖的方式抑制 MCF-7 和 HepG2 的增殖。Epimedokoreanin B 能显著抑制 N (δ) -(羧甲基)赖氨酸(CML)和 N (Ï) -(羧甲基)精氨酸(CMA)的形成,可通过抑制高级糖化终产物(AGEs)预防糖尿病的临床并发症。 | |||
TN1642 |
Ferruginol
铁锈罗汉柏醇 |
BCL; PARP; Caspase | Apoptosis; Chromatin/Epigenetic; DNA Damage/DNA Repair; Proteases/Proteasome |
Ferruginol has anti-plasmodial, leishmanicidal, anti-ulcerogenic, cardioprotective, anticancer, anti-oxidative and anti-inflammatory activities, it can induce apoptosis in non-small cell lung cancer (NSCLC) cells. | |||
T81132 |
Soladulcoside A
|
Others | Others |
Soladulcoside A,一种甾体糖苷及抗肿瘤剂,源自龙葵全株。该化合物可抑制A549细胞,并展示对治疗非小细胞肺癌(NSCLC)等癌症的潜在应用。 | |||
T35895 |
Ingenol 3,20-dibenzoate
|
Others | Others |
Ingenol 3,20-dibenzoate is a powerful activator of protein kinase C (PKC) isoforms. It effectively induces the translocation of nPKC-delta, -epsilon, and -theta as well as PKC-mu from the cytosolic fraction to the particulate fraction. Through de novo synthesis of macromolecules, it triggers apoptosis with characteristic morphology. Moreover, Ingenol 3,20-dibenzoate enhances IFN-γ production and degranulation in NK cells, particularly when stimulated by NSCLC cells[1][2]. | |||
TN3525 |
Boehmenan
|
ERK; Phosphatase; EGFR; PARP; MEK; Wnt/beta-catenin; Akt; Caspase; STAT; p53 | Angiogenesis; Apoptosis; Chromatin/Epigenetic; Cytoskeletal Signaling; DNA Damage/DNA Repair; JAK/STAT signaling; MAPK; Metabolism; PI3K/Akt/mTOR signaling; Proteases/Proteasome; Stem Cells; Tyrosine Kinase/Adaptors |
(±)-Boehmenan shows potent protein-tyrosine phosphatase 1B (PTP1B) inhibitory activity in vitro with the IC(50) values of 43.5 uM, it inhibits PTP1B activity in a competitive manner. Boehmenan exhibits the potent cytotoxic effects against many cancer cell |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-03958 |
TGF alpha Protein, Human, Recombinant
transforming growth factor α,转化生长因子,transforming growth fact... |
Human | E. coli |
The miR-137 served as a tumor suppressor in non-small cell lung cancer (NSCLC) and its suppressive effect is mediated by repressing TGFA expression. TGFA gene expression was significantly higher in tumor tissues compared to adjacent normal tissue and high TGFA gene expression strongly correlated with poor survival in patients with lung adenocarcinoma, and miR-374a suppresses lung adenocarcinoma cell proliferation and invasion via targeting TGFA gene expression. Transforming growth factor alpha (... | |||
TMPY-00476 |
ITGB1 Protein, Human, Recombinant (His)
VLAB,integrin, beta 1 (fibronectin receptor, beta polypeptid... |
Human | HEK293 Cells |
ITGB1 (Integrin Subunit Beta 1) is a Protein Coding gene. This gene encodes a beta subunit, which is a type 1 transmembrane protein of the integrin beta chain family. ITGB1 is a heterodimeric cell-surface receptor involved in cell functions such as proliferation, migration, invasion, and survival. ITGB1 has been recognized to play a major role in tumor growth, invasion, and metastasis. Using luciferase assays, the researcher identified ITGB1 as a direct target of miR-134. ITGB1 is a direct targe... | |||
TMPK-01034 |
SEMA4B Protein, Mouse, Recombinant (His)
SEMA4B,SemC,Semaphorin-C,MGC131831,Semaphorin-4B,KIAA1745,SE... |
Mouse | HEK293 Cells |
Semaphorin 4B (SEMA4B) inhibits the invasion of non-small cell lung cancer (NSCLC) through PI3K-dependent suppression of MMP9 activation. SEMA4B may induce FoxO1 nuclear retention through suppressing PI3K/Akt signaling pathway, which subsequently inhibited cell growth through the direct nuclear target of FoxO1, p21. A role of SEMA4B in suppressing NSCLC growth, besides its role in inhibiting cell metastasis, and highlights SEMA4B as a promising therapeutic target for NSCLC. | |||
TMPK-00341 |
ALCAM Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated
ALCAM,KG-CAM,MEMD,CD166,CD6L |
Human | HEK293 Cells |
Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM. ALCAM Protein (Primary Amine Labeling), Human, Recombinant (His), Biotinylated is expressed ... | |||
TMPY-04985 |
TMPRSS11D Protein, Human, Recombinant (His)
transmembrane protease, serine 11D,HAT |
Human | HEK293 Cells |
TMPRSS11D (HAT) belongs to the large type II transmembrane serine protease (TTSP) family, participating in various biological and physiological processes. TMPRSS11D protein expression in tumorous tissues were correlated with NSCLC patients' clinical characteristics and overall survival. Both TMPRSS11D mRNA and protein expression levels were significantly higher in NSCLC tumorous tissues than in adjacent normal tissues. High TMPRSS11D protein expression was associated with high TNM stages, and hi... | |||
TMPY-02259 |
FKBP25/FKBP3 Protein, Human, Recombinant (GST)
FKBP-25,PPIase,FKBP25,FK506 binding protein 3,FKBP-3 |
Human | E. coli |
FKBP3 is a member of FK506-binding proteins (FKBPs). miR-145-5p overexpression suppressed cell proliferation of NSCLC cells which was abrogated by FKBP3 overexpression, that FKBP3/Sp1/HDAC2/p27 control cell proliferation during NSCLC development. | |||
TMPK-00340 |
ALCAM Protein, Human, Recombinant (His & Avi), Biotinylated
CD166,CD6L,KG-CAM,ALCAM,MEMD |
Human | HEK293 Cells |
Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM. ALCAM Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian... | |||
TMPK-00339 |
ALCAM Protein, Mouse, Recombinant (His & Avi), Biotinylated
CD6L,ALCAM,MEMD,KG-CAM,CD166 |
Mouse | HEK293 Cells |
Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM. ALCAM Protein, Mouse, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian... | |||
TMPY-04375 |
Casein Kinase 1 alpha Protein, Human, Recombinant (GST)
CKIa,casein kinase 1, alpha 1,casein kinase 1, α1,CK1a,Casei... |
Human | Baculovirus Insect Cells |
Casein kinase I isoform alpha, also known as CKI-alpha, CK1 and CSNK1A1, is a cytoplasm protein which belongs to theprotein kinase superfamily, CK1 Ser/Thr protein kinase family and casein kinase I subfamily. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. High expression of CSNK2A1, or concomitantly high expression of CSNK2A1, are independent prognostic factors of poor survival in NSCLC patients. CSNK2A1 are use... | |||
TMPY-03795 |
EIF5A2 Protein, Human, Recombinant (His)
eIF5AII,eukaryotic translation initiation factor 5A2,EIF-5A2 |
Human | E. coli |
Eukaryotic translation initiation factor 5A2 (EIF5A2) has been demonstrated to be upregulated in numerous types of human cancer and is associated with cancer progression. Silencing of EIF5A2 in the NSCLC cells resulted in the downregulation of the tumorigenic proteins, apoptosis regulator Bcl-2 and myc proto-oncogene protein, and upregulation of E-cadherin, suggesting that EIF5A2 promotes proliferation and metastasis through these proteins. EIF5A2 may therefore serve as a novel therapeutic targe... | |||
TMPY-02210 |
Serpin B9 Protein, Human, Recombinant (His)
CAP-3,PI-9,CAP3,PI9,serpin peptidase inhibitor, clade B (ova... |
Human | Baculovirus Insect Cells |
SerpinB9, also known as Cytoplasmic antiproteinase 3, CAP-3, Peptidase inhibitor 9, SERPINB9 and PI-9, is a cytoplasm protein that belongs to the serpin family and Ov-serpin subfamily. Serpin-B9 ( CAP-3 / PI-9 ) is the only known human intracellular inhibitor of granzyme B (GrB), the effector molecule in immunity against cytomegalovirus (CMV) and in renal allograft rejection. Serpin-B9 and SPI-6 expression in immune-privileged cells, APCs, and CTLs protect these cells against the actions of gran... | |||
TMPY-02399 |
TRF1 Protein, Human, Recombinant (His)
TRF,telomeric repeat binding factor (NIMA-interacting) 1,hTR... |
Human | Baculovirus Insect Cells |
Telomeric repeat binding factor 1 (TRF1), also known as TERF1, the shelterin complex, which modulates the telomere structures. TRF1 protein structure contains a C-terminal Myb motif, a dimerization domain near its N-terminus and an acidic N-terminus. Pin2/TRF1 was originally identified as a protein bound to telomeric DNA (TRF1) and as a protein involved in mitotic regulation (Pin2). Pin2/TRF1 negatively regulates telomere length and importantly, its function is tightly regulated during the cell ... | |||
TMPJ-00281 |
CADM1 Protein, Mouse, Recombinant (hFc)
IgSF4,NECL-2,Nectin-like protein 2,Immunoglobulin superfamil... |
Mouse | HEK293 Cells |
Cell adhesion molecule 1(CADM1) is a single-pass type I membrane protein and belongs to the nectin family. It contains 2 Ig-like C2-type (immunoglobulin-like) domains and 1 Ig-like V-type (immunoglobulin-like) domain. CADM1 acts as a tumor suppressor in non-small-cell lung cancer (NSCLC) cells. Interaction with CRTAM promotes natural killer (NK) cell cytotoxicity and interferon-gamma (IFN-gamma) secretion by CD8+ cells in vitro as well as NK cell-mediated rejection of tumors expressing CADM3 in... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T72818 |
Dosimertinib-d3
|
||
Dosimertinib-d3是一种有效的口服活性EGFR 抑制剂。Dosimertinib-d3降低 p-EGFR 和 p-ERK 蛋白水平的表达。Dosimertinib-d3显示出抗增殖和抗肿瘤活性。Dosimertinib-d3具有非小细胞肺癌 (NSCLC) 研究的潜力。 | |||
TMIH-0413 |
Osimertinib-d6
|
||
Osimertinib-d6 是 Osimertinib 的氘代化合物。Osimertinib 的 CAS 号为 1421373-65-0。Osimtinib 是一种小分子酪氨酸激酶受体抑制剂和抗肿瘤剂,用于治疗选定形式的晚期非小细胞肺癌,其有效抑制 L858R 和 L858R/T790M EGFR,IC50 为 12 和 1 nM。 |